Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Midazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 0.74 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 0.74 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 0.74 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 0.74 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.74 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.74 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | DRD3 | P35462 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PTAFR | P25105 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midazolam SCHEMBL28086280 | 0.91 | OPRK1 (0.67) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL29735381 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL29480459 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL5783371 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL29565146 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL35061 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL29357425 | 0.89 | OPRK1 (1.00) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL29445200 | 0.88 | OPRK1 (0.98) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL1311204 | 0.88 | OPRK1 (0.98) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 | |
| Midazolam SCHEMBL41265 | 0.88 | OPRK1 (0.98) | OPRK1PDE4DCYP3A4SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786518-B2 | Compositions and methods of treating HIV | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-29 | — | — | US | disclosed |
| EP-3654951-A1 | COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018676-A1 | COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV | Janssen Sciences Ireland Unlimited Company (IE) | 2019-01-24 | — | — | WO | disclosed |
| US-20190022113-A1 | Compositions and Methods of Treating HIV | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022113-A1 | Compositions and Methods of Treating HIV | SAMHD1, TYMP, MTAP | GABRA1 2952/4885GABRA5 2650/4885GABRA2 3523/4885 |
| US-10786518-B2 | Compositions and methods of treating HIV | SAMHD1, TYMP, MTAP | GABRA1 2952/4885GABRA5 2650/4885GABRA2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.